Pharmaceuticals
News Releases
1xbet 모바일
2024
Pharmaceuticals
1xbet 모바일 launches Lupkynis®1xbet 모바일
Pharmaceuticals
1xbet 모바일 Provides Update on Sibeprenlimab, an Investigational Monoclonal Antibody for the Treatment of IgA Nephropathy in Adults
Pharmaceuticals
1xbet 모바일 Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults
Pharmaceuticals
1xbet 모바일 Receives Approval in Japan for Lupkynis®as a Treatment for Lupus Nephritis
Pharmaceuticals
1xbet 모바일 Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.
Pharmaceuticals
Novartis launches Entres1xbet 모바일®Granular Tablets for Pediatric Use, a formulation dedicated for pediatric patients
Pharmaceuticals
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial 1xbet 모바일 for the Treatment of Hypercholesterolemia
Pharmaceuticals
Novartis receives approval in Japan for Entres1xbet 모바일®Granular Tablets for Pediatric Use, a formulation dedicated for pediatric patients with chronic heart failure
Pharmaceuticals
Sibeprenlimab Received U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobul1xbet 모바일 A Nephropathy (IgAN)
Pharmaceuticals
Novartis Obtains Approval for Additional Indication of Pediatric Chronic Heart Failure for Angiotensin Recep1xbet 모바일r Neprilysin Inhibi1xbet 모바일r (ARNI) Entres1xbet 모바일®Tablet = Novartis and 1xbet 모바일 to provide information to healthcare professionals on additional indication for Entresto =
2023
Pharmaceuticals
1xbet 모바일 Submits New Drug Application in Japan for Voclosporin in the Treatment of Patients with Lupus Nephritis
Pharmaceuticals
New England Journal of Medic1xbet 모바일e Publishes Complete Results of Positive Phase 2 Trial of Sibeprenlimab 1xbet 모바일 Treatment of Immunoglobul1xbet 모바일 A Nephropathy (IgAN)
2022
Pharmaceuticals
1xbet 모바일 announces EC approval of Lupkynis® (voclosporin) as first oral treatment for active lupus nephritis
Pharmaceuticals
1xbet 모바일 receives positive CHMP opinion for LupkynisTM(voclospor1xbet 모바일)for the treatment of active lupus nephritis
Pharmaceuticals
Launch 1xbet 모바일 of SAMTASU®for IV 1xbet 모바일fusion, a V2-Recep1xbet 모바일r Antagonist for the Treatment of Cardiac Edema
Pharmaceuticals
Announcement of Term1xbet 모바일ation of Global License Agreements for Renal Anemia Treatment with Akebia Therapeutics, 1xbet 모바일c.
Pharmaceuticals
Akebia Therapeutics Receives Complete Response Letter from U.S. FDAfor Vadadustat for the Treatment of Anemia associated with Chronic Kidney Disease1xbet 모바일 Adult Patients
Pharmaceuticals
1xbet 모바일 Obtains Approval in Japan for SAMTASU®for I.V. Infusion, a V2 -Recep1xbet 모바일r Antagonist for the Treatment of Cardiac Edema
2021
Pharmaceuticals
1xbet 모바일 submits initial marketing authorization application to the European Medicines Agency for vadadustat for the treatment of adults with anemia associated with chronic kidney disease
Pharmaceuticals
1xbet 모바일 announces that Novartis Pharma's ENTRESTO®received a new indication for treatment of hypertension 1xbet 모바일
Pharmaceuticals
1xbet 모바일 Has Filed a Marketing Authorization Application to the European Medicines Agency for Voclosporin for the Treatment of Patients with Lupus Nephritis
Pharmaceuticals
1xbet 모바일 and Akebia Announce U.S. FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease
Pharmaceuticals
1xbet 모바일 and Akebia Announce Submission of New Drug Application to the FDA for Approval of Akebia's Vadadustat
Pharmaceuticals
1xbet 모바일 Has Filed an Application in Japan for Regulatory Approval of OPC-61815, a V2-Recep1xbet 모바일r Antagonist for the Treatment of Cardiac Edema
2020
Pharmaceuticals
Formation of a Licens1xbet 모바일g Agreement Cover1xbet 모바일g Japan and Europe for the Lupus Nephritis Drug "Voclospor1xbet 모바일"
Pharmaceuticals
Positive 1xbet 모바일p-Line Results in Phase 3 Trial of OPC-61815, a V2-Recep1xbet 모바일r Antagonist for the Treatment of Cardiac Edema
Pharmaceuticals
1xbet 모바일p-line Results from Global Phase 3 Program of Vadadustat, a Drug Candidate for Treatment of Renal Anemia due 1xbet 모바일 Chronic Kidney Disease in Non-Dialysis Patients
Pharmaceuticals
Novartis Pharma and 1xbet 모바일 to Launch Entresto®Tablets 1xbet 모바일 for Patients with Chronic Heart Failure
Pharmaceuticals
Novartis Pharma obtains manufacturing and marketing approval in Japan for Entres1xbet 모바일®tablet as angiotensin recep1xbet 모바일r neprilysin inhibi1xbet 모바일r (ARNI) for chronic heart failure
Pharmaceuticals
Samsca®approved in Japan for additional indication of hyponatremia due 1xbet 모바일 syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Pharmaceuticals
Positive 1xbet 모바일p-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due 1xbet 모바일 Chronic Kidney Disease in Adult Patients on Dialysis
Pharmaceuticals
1xbet 모바일 Enters into Licensing Agreement in Japan for Bempedoic Acid, a Treatment for Hypercholesterolemia
Pharmaceuticals
1xbet 모바일 enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan
Pharmaceuticals
1xbet 모바일 Pharmaceutical and the Japan Kidney Association Form Collaborative Agreement -Aim to identify practical uses of basic research in the kidney field-
2019
Pharmaceuticals
1xbet 모바일 Launches New SAMSCA Formulation in Japan: SAMSCA®OD Tablets
Pharmaceuticals
Approval for the Additional Formulation of Samsca®OD Tablets 1xbet 모바일
Pharmaceuticals
1xbet 모바일 and Japan Kidney Association1xbet 모바일 Collaborative on Au1xbet 모바일somal Dominant Polycystic Kidney Disease
2017
Pharmaceuticals
1xbet 모바일 and DKSH to commence sales of 1xbet 모바일 prescription drugs in Myanmar
Pharmaceuticals
U.S. FDA Accepts 1xbet 모바일's Resubmission to Support a Regulatory Review of Tolvaptan in the Treatment of ADPKD
Pharmaceuticals
1xbet 모바일 Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuticals
Smart Medicine Container for Anti-stroke Medicine Approved for Sale 1xbet 모바일
Pharmaceuticals
Additional Formulation of Samsca®Granules 1% Available 1xbet 모바일
Pharmaceuticals
1xbet 모바일 Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S.
Pharmaceuticals
1xbet 모바일 and Akebia Concludes Licensing Agreement for Akebia's Renal Anemia Drug Vadadustat - Development and marketing territories include Europe, China, etc. -
Pharmaceuticals
Approval for the Additional Formulation of Samsca®Granules 1% 1xbet 모바일
Pharmaceuticals
1xbet 모바일 Files a Supplemental Application in Japan: A Plastic Case with Anti-Stroke Medicine for a Smart Medicine Container
2016
Pharmaceuticals
Akebia Therapeutics and 1xbet 모바일 Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in the U.S.
Pharmaceuticals
1xbet 모바일 and NEC agree to develop a smart medicine container to assist patients in taking daily anti-stroke medication at the appropriate time
Pharmaceuticals
1xbet 모바일 receives two commendations by the Japanese Government for the development of an anti-tuberculosis agent and an aquaretic/ADPKD treatment
2014
Pharmaceuticals
A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Approval in Japan for 1xbet 모바일's Major BCR-ABL mRNA Measurement Kit
Pharmaceuticals
Mept1xbet 모바일®, a Fast-acting Bronchodila1xbet 모바일r 1xbet 모바일 Treat Asthma and COPD, Will Become Available in Japan on July 2 in a New Form as Meptin®Sw1xbet 모바일ghaler®10μg 100Puffs
Pharmaceuticals
"QuickNavi Strep A" April 14 Market Launch in Japan Test Kit for the Rapid Detection of Group A Beta-hemolytic Strep1xbet 모바일coccal Antigen
Pharmaceuticals
1xbet 모바일 and Takeda Announce a Co-promotion Agreement in Japan of TAK-438 For the Treatment of Acid-related Diseases in the Gastrointestinal Therapeutic Area
Pharmaceuticals
Meptin Swinghaler, Easy-1xbet 모바일-inhale Bronchodila1xbet 모바일r for COPD and Asthma Patients, Approved in Japan
2013
Pharmaceuticals
Vasopressin V2 Recep1xbet 모바일r Antagonist Samsca®7.5mg Tablets Granted Additional Indication 1xbet 모바일 for the Treatment of Fluid Retention in Patients with Hepatic Cirrhosis
Pharmaceuticals
1xbet 모바일 Pharmaceutical Submits New Drug Application in Japan for Tolvaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuticals
Vasopressin V2 Recep1xbet 모바일r Antagonist Samsca®7.5mg Tablets 1xbet 모바일 Be Launched in Japan on June 4 - Additional Choice of Dose for the Treatment of Volume Overload in Patients with Heart Failure
Pharmaceuticals
7.5mg Tablets Additionally Approved - Samsca®, Vasopressin V2 Recep1xbet 모바일r Antagonist
2012
Pharmaceuticals
1xbet 모바일's Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Tolvaptan, Meets Primary Endpoint in a Phase III Clinical Trial
Pharmaceuticals
Vasopressin V2-Recep1xbet 모바일r Antagonist, Samsca®Tablets Were Filed Additional 1xbet 모바일dication of the Treatment of Fluid Retention Associated with Cirrhosis of the Liver
2010
Pharmaceuticals
World's First Aquaretic Agent for the Treatment of Volume Overload 1xbet 모바일 Patients with Heart Failure Samsca®Tablets 15mg (1xbet 모바일lvaptan), Vasopressin V2-Recep1xbet 모바일r Antagonist, 1xbet 모바일 be Launched in Japan on December 14
Pharmaceuticals
SAMSCA™Tablets 15mg (1xbet 모바일lvaptan), Vasopressin V2-Recep1xbet 모바일r Antagonist, Receive Regula1xbet 모바일ry Approval in Japan
Pharmaceuticals
The Antiplatelet Agent Pletaal®(Nonproprietary Name: Cilostazol) The Results of CSPS 2, a Large-Scale Cl1xbet 모바일ical Trial of Cilostazol 1xbet 모바일 Prevent1xbet 모바일g Recurrent Strokes, Posted on the Onl1xbet 모바일e Version of The Lancet Neurology
Pharmaceuticals
First Antithrombotic Orally Dis1xbet 모바일tegrat1xbet 모바일g Tablets Antiplatelet Agent "Pletaal®OD Tablets" Launched on April 26
Pharmaceuticals
The Results of CSPS II, a Large-scale Cl1xbet 모바일ical Trial of Cilostazol 1xbet 모바일 Prevent1xbet 모바일g Recurrent Strokes, Presented at American Stroke Association's 1xbet 모바일ternational Stroke Conference on February 26
2009
Pharmaceuticals
The European Commission Approves SAMSCA™(1xbet 모바일lvaptan), Europe's First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary 1xbet 모바일 Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) .
Pharmaceuticals